Last Updated: November 16, 2026

Details for Patent: 9,493,470

« Back to Dashboard


Summary for Patent: 9,493,470
Title:Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Abstract:Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyljbenzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methyl piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein. The instant application is directed to novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl}phenyl}benzamide and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, compositions comprising such crystalline forms, and to methods of their preparation and use.
Inventor(s):Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep Sharma
Assignee: Takeda Pharmaceuticals USA Inc
Application Number:US14/651,577
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,493,470
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

US Patent 9,493,470: Ponatinib Hydrochloride Form A Claims, Expiration, Orange Book Status, and Generic Entry Risk

US Patent 9,493,470 protects a crystalline polymorph of ponatinib hydrochloride, identified as crystalline Form A. Its core protection is defined by powder X-ray diffraction, not by the ponatinib molecule itself. The patent also covers material containing more than 90% Form A, pharmaceutical compositions, and treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

The patent was assigned to ARIAD Pharmaceuticals and is now associated with Takeda following Takeda's acquisition of ARIAD. The patent issued on November 15, 2016, from a filing claiming priority to December 21, 2012. The expected patent-term expiration is December 21, 2033, subject to any adjustment or extension recorded in the USPTO and FDA databases. The relevant commercial product is Iclusig, marketed by Takeda.

The patent is commercially important because it covers the solid form used in the marketed ponatinib hydrochloride product. A generic applicant may avoid literal infringement by using a different polymorph, but it would need to establish that its active pharmaceutical ingredient, manufacturing process, and finished dosage form do not contain Form A within the scope of the claims.

What does US Patent 9,493,470 protect?

US 9,493,470 protects crystalline Form A of ponatinib hydrochloride and products containing that form.

The claims divide into four technical categories:

Claim category Claims Protected subject matter
Crystalline Form A 1, 3, 4 Form A defined by XRPD peak positions or the diffraction pattern in Figure 4
Purity or polymorphic content 2, 12 Ponatinib hydrochloride containing more than 90% Form A
Pharmaceutical compositions 5-7, 10, 13-15 Compositions containing Form A, including compositions consisting essentially of Form A
Treatment methods 8, 9, 11, 16, 17 Treating CML or Ph+ ALL with compositions containing Form A

The patent does not broadly claim all ponatinib salts, all ponatinib polymorphs, the ponatinib molecule itself, or every ponatinib tablet formulation. Its central limitation is the crystalline Form A solid-state structure.

How do claims 1 and 4 define ponatinib Form A?

Claims 1 and 4 use XRPD peak selections to identify Form A.

Claim 1 requires at least five 2θ values, within ±0.3 degrees, selected from nine listed values:

5.9, 7.1, 10.0, 12.5, 16.4, 19.3, 21.8, 23.8, and 26.1 degrees.

Claim 4 uses a longer list of 22 possible peaks:

5.9, 7.1, 10.0, 12.5, 13.6, 14.1, 15.0, 16.4, 17.7, 18.6, 19.3, 20.4, 21.8, 22.3, 23.8, 24.9, 26.1, 27.0, 28.4, 30.3, 31.7, and 35.1 degrees.

Claim 1 versus claim 4

Issue Claim 1 Claim 4
Number of candidate peaks 9 22
Required matching peaks At least 5 At least 5
XRPD tolerance ±0.3° 2θ ±0.3° 2θ
Additional peaks Not required Not required
Practical scope Broad peak-selection definition Broader candidate peak set, but potentially more technically discriminating
Dependent claims Claims 2, 3, 5-11 Claims 12-17

Because both claims require only five selected peaks, they do not require the accused material to show every listed reflection. That drafting choice increases literal scope but creates potential validity and construction issues involving peak selection, measurement conditions, and whether the claimed combination reliably distinguishes Form A from other crystalline material.

What is the scope of the more-than-90% Form A claims?

Claims 2 and 12 cover crystalline ponatinib hydrochloride in which more than 90% of the material is Form A.

These claims are directed to polymorphic composition rather than a single crystal or perfectly pure solid form. The claims may capture material containing a minor amount of another polymorph, amorphous material, or other crystalline impurity, provided Form A exceeds 90%.

The key enforcement question is how the 90% threshold is measured. Potential analytical methods include XRPD quantitative phase analysis, differential scanning calorimetry, microscopy, solid-state characterization, and validated process-control methods. The patent claims do not, in the quoted language, specify a single quantitative protocol.

A generic applicant could face infringement exposure if its API is nominally described as another form but contains more than 90% Form A. Conversely, a Form A process that produces less than the claimed threshold could avoid claims 2 and 12 while remaining exposed to claims 1 or 4.

What pharmaceutical formulations are protected?

Claims 5-7 and 10, 13-15 cover pharmaceutical compositions containing crystalline Form A.

Claims 5, 6, 10, 13 and 14 require at least one pharmaceutically acceptable carrier, vehicle or excipient. These claims can reach conventional oral dosage forms if the finished product contains the claimed Form A.

Claims 7 and 15 use "consisting essentially of." That transition generally permits components that do not materially affect the basic and novel characteristics of the composition. It is narrower than "comprising" but broader than "consisting of."

The claims do not expressly require:

  • A particular tablet strength
  • A specific dosage regimen
  • A specific excipient
  • A coating system
  • A dissolution profile
  • A particle-size distribution
  • A manufacturing process
  • A particular brand name
  • A particular route of administration

The marketed Iclusig dosage forms are oral tablets containing ponatinib hydrochloride in 15 mg, 30 mg and 45 mg strengths. The patent's composition claims may cover those products because of the Form A active ingredient, but the claims are not limited to those strengths.

What method-of-use protection does US 9,493,470 provide?

Claims 8, 9, 11, 16 and 17 cover treatment of:

  • Chronic myeloid leukemia
  • Philadelphia chromosome-positive acute lymphoblastic leukemia

Each method claim requires administering a therapeutically effective amount of a pharmaceutical composition containing Form A.

The treatment claims are narrower than a general ponatinib method-of-treatment patent because they require the claimed crystalline form or a composition containing it. They may be relevant to induced infringement if a generic label directs use for CML or Ph+ ALL and the generic product contains Form A.

A generic applicant could seek a section viii statement or other labeling strategy only for indications protected by method-of-use claims that are properly listed and legally enforceable. That strategy does not eliminate risk from product claims covering the API or composition.

When does US Patent 9,493,470 lose exclusivity?

The ordinary patent-term expiration date is expected to be December 21, 2033, based on the patent's December 21, 2012 priority date and a 20-year term framework. The controlling expiration should be confirmed against the USPTO patent-term record and any applicable patent-term adjustment.

Milestone Date
Earliest claimed priority December 21, 2012
Patent issued November 15, 2016
Expected ordinary expiration December 21, 2033
FDA approval of Iclusig December 14, 2012
Product Ponatinib hydrochloride tablets

Patent expiration is separate from FDA regulatory exclusivity. Iclusig received orphan-drug exclusivity for its initial indications, and the product also had new-chemical-entity exclusivity. Those FDA periods do not extend the patent term, although pediatric exclusivity or patent-term extension could affect actual market timing if granted and applicable.

What is the Orange Book status of ponatinib and patent 9,493,470?

The FDA Orange Book identifies patents submitted by the new-drug application holder for approved products. Iclusig is approved under NDA 203469. The relevant Orange Book entries should be reviewed by patent number, product strength, and submission date because listing status can change through FDA updates, delisting requests, certifications, and court decisions. The FDA Orange Book is the controlling public source for current listing status. [1]

US 9,493,470 is the type of solid-form patent that can materially affect an ANDA applicant even when the underlying compound patent has expired or is approaching expiry. If listed against Iclusig, an ANDA applicant would generally need to provide a paragraph IV certification to challenge the patent or a paragraph III certification accepting delayed approval until expiration.

A patent listing does not establish validity or enforceability. It establishes the regulatory framework for patent certifications and the potential for a 30-month stay following timely patent litigation under the Hatch-Waxman statute.

Which companies are challenging ponatinib patents?

Publicly available litigation and FDA sources should be read together. The FDA Orange Book records patent listings and certifications but does not provide a complete litigation history for every ANDA. PACER, district court dockets, and Federal Circuit records are needed to identify each paragraph IV notice recipient and the procedural status of any action.

For US 9,493,470, the principal commercial challengers would be generic manufacturers filing ANDAs for ponatinib hydrochloride tablets. A complete current challenger list cannot be established from the claim text alone. The relevant risk indicators are:

  1. An ANDA filing with a paragraph IV certification against the patent.
  2. A Hatch-Waxman infringement action filed within 45 days.
  3. A settlement or license agreement.
  4. A tentative approval date.
  5. A court judgment or covenant not to sue.
  6. A product launch before patent expiration under an authorized entry arrangement.

No biosimilar pathway applies. Ponatinib is a chemically synthesized small molecule, not a biological product. Generic competition would proceed through section 505(j) of the Federal Food, Drug, and Cosmetic Act, not the section 351(k) biosimilar pathway. [2]

What patent litigation affects Iclusig generic entry?

The commercial litigation risk is likely to center on three patent layers:

Patent layer Subject matter Generic-entry significance
Compound patents Ponatinib chemical structure May expire earlier than the solid-form patent
Method patents CML, Ph+ ALL and other therapeutic uses May support label-based infringement claims
Solid-form patent Ponatinib hydrochloride Form A May block or delay products using the same polymorph

A generic applicant can challenge the solid-form patent through several theories:

  • The XRPD definition is anticipated by prior-art crystalline ponatinib hydrochloride.
  • Form A was obvious to prepare from known ponatinib hydrochloride.
  • The selected peaks do not adequately distinguish Form A.
  • The ±0.3-degree limitation creates measurement or indefiniteness issues.
  • The claims lack adequate written description or enablement across their full scope.
  • The generic product uses a different polymorph and does not infringe.
  • The finished product does not contain more than 90% Form A.
  • The method claims are not infringed because the proposed label omits protected uses.

The patent owner would likely rely on batch testing, XRPD comparison, solid-state identity, process history, and quantitative phase analysis. A design-around product would require a reproducibly different polymorph or amorphous form, plus controls preventing conversion to Form A during milling, granulation, compression, storage, and dissolution.

How strong is the patent estate for ponatinib?

The estate is stronger against a generic that copies the marketed active ingredient and manufacturing approach than against a generic that develops an independently characterized solid form.

Strengths

  • The patent covers the commercial active ingredient in a specific crystalline state.
  • Claims reach both the API and finished pharmaceutical compositions.
  • The more-than-90% claims can capture material with limited polymorphic contamination.
  • Treatment claims may create induced-infringement exposure for CML and Ph+ ALL labeling.
  • Form A can be difficult to avoid if it is the most stable or manufacturable form.

Vulnerabilities

  • XRPD peak-selection claims can raise anticipation and obviousness issues.
  • Claim 1 and claim 4 require only five peaks from relatively long lists.
  • The quoted claims do not specify all analytical conditions needed for reproducibility.
  • A generic can investigate alternative polymorphs, solvates, hydrates or amorphous material.
  • Composition claims may depend on proving that the API in the finished tablet remains Form A.
  • Method claims may be limited by label carve-outs and treatment-indication language.

The patent is commercially meaningful but does not create absolute exclusivity over ponatinib. Its practical value depends on whether Form A is necessary for acceptable drug-product performance and whether an alternative form can be manufactured at commercial scale.

What generic launch scenarios exist?

Scenario 1: Form A product after patent expiration

A generic applicant files an ANDA, certifies against the listed patents, and launches after December 21, 2033. This is the lowest litigation-risk scenario but provides the least commercial timing advantage.

Scenario 2: Paragraph IV challenge and authorized settlement entry

The applicant challenges the patent and reaches a settlement allowing entry before the expected expiration date. The entry date, license scope, supply terms and restrictions would determine commercial value.

Scenario 3: Non-Form-A design-around

The applicant develops a different polymorph, hydrate, solvate or amorphous form and demonstrates that the product does not contain Form A or more than 90% Form A. This route creates technical, regulatory and manufacturing risks.

Scenario 4: Litigation victory

The applicant obtains a judgment that the patent is invalid, unenforceable or not infringed. The timing depends on district court proceedings, appeal rights and any separate patents covering the compound, use or formulation.

Scenario 5: Limited-label launch

The applicant removes protected indications from its label. This may reduce method-of-use risk but does not resolve API or composition claims covering Form A.

How does US 9,493,470 compare with competing patent estates?

The patent should be evaluated against the complete Iclusig estate rather than in isolation.

Estate component Primary barrier Approximate commercial role
Ponatinib compound patents Chemical identity Earlier basic protection
Therapeutic-use patents CML and Ph+ ALL treatment Supports label and induced-infringement enforcement
Formulation patents Tablet composition, if listed May cover finished dosage technology
US 9,493,470 Form A ponatinib hydrochloride Potential late-expiring solid-form barrier
Manufacturing patents Crystallization or purification process May restrict API production routes

The key comparison is between compound-patent expiry and the 2033 expected expiry of the Form A patent. If the basic compound patents expire first, US 9,493,470 may become the principal barrier to a conventional ponatinib generic.

What revenue exposure does the patent create?

The patent's value is linked to the US market for Iclusig and the feasibility of generic substitution. It can delay generic erosion if:

  • Iclusig uses Form A in every commercial strength.
  • The Form A process is the lowest-cost route.
  • Alternative polymorphs lack equivalent stability or dissolution.
  • FDA-approved generic products are likely to use Form A.
  • Settlements restrict early entry.

Revenue exposure is not determined by patent term alone. It also depends on generic approval timing, payer substitution, authorized generic strategy, disease prevalence, competing tyrosine kinase inhibitors, and the size of the remaining CML and Ph+ ALL market.

What manufacturing and IP barriers apply?

The main manufacturing barrier is polymorph control. A commercial process must control:

  • Solvent system
  • Temperature profile
  • Seeding
  • Supersaturation
  • Water content
  • Drying conditions
  • Milling energy
  • Storage humidity
  • Conversion during tablet manufacture

Even a product designed around a non-Form-A polymorph may convert into Form A during processing or storage. That creates both infringement risk and regulatory comparability issues.

The patent does not, based on the quoted claims, expressly claim a crystallization process. A process patent or trade secret may nevertheless provide additional protection if the commercial Form A process is difficult to replicate.

Key Takeaways

  1. US 9,493,470 is a solid-form patent covering crystalline Form A of ponatinib hydrochloride.
  2. Claims 1 and 4 use XRPD peak selections with a ±0.3-degree tolerance.
  3. Claims 2 and 12 cover ponatinib hydrochloride containing more than 90% Form A.
  4. Claims 5-7 and 10, 13-15 extend protection to pharmaceutical compositions.
  5. Claims 8, 9, 11, 16 and 17 cover treatment of CML and Ph+ ALL.
  6. The expected ordinary expiration date is December 21, 2033, subject to the USPTO patent-term record.
  7. The patent does not cover every ponatinib salt or polymorph.
  8. A generic using Form A faces direct product and composition-claim risk.
  9. A non-Form-A design-around is possible in principle but requires robust solid-state characterization and process control.
  10. Ponatinib is a small molecule, so generic competition proceeds through ANDA litigation, not biosimilar litigation.

FAQs About Ponatinib Patent 9,493,470

Is US 9,493,470 a compound patent?

No. It is principally a crystalline solid-form patent for ponatinib hydrochloride Form A. The patent does not broadly claim the ponatinib molecular structure.

Does the patent cover all ponatinib hydrochloride?

No. It covers the claimed crystalline Form A and material containing more than 90% Form A. A different crystalline form, hydrate, solvate or amorphous form may fall outside the claims, subject to testing and claim construction.

Can a generic manufacturer avoid the patent by changing the tablet excipients?

Usually not if the generic API contains Form A. Claims 1, 2 and 4 directly target the crystalline active ingredient, while composition claims target products containing it. Excipients alone may not avoid infringement.

Does the patent cover ponatinib for every cancer indication?

No. The quoted treatment claims are limited to CML and Ph+ ALL. Other indications would require separate claim analysis and may implicate different patents.

Is a ponatinib biosimilar possible under section 351(k)?

No. Ponatinib is a chemically synthesized small molecule. A competing product would generally use the ANDA pathway under section 505(j), subject to applicable patents and exclusivity.

References

  1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
  2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
  3. U.S. Patent No. 9,493,470. (2016). Crystalline forms of ponatinib hydrochloride. U.S. Patent and Trademark Office.
  4. U.S. Food and Drug Administration. (2012). Iclusig prescribing information. Takeda Pharmaceuticals U.S.A., Inc.
  5. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculator resources. https://www.uspto.gov/patents/laws/patent-term-calculator

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,493,470

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA ⤷  Start Trial
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ⤷  Start Trial
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ⤷  Start Trial
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,493,470

PCT Information
PCT FiledDecember 12, 2013PCT Application Number:PCT/US2013/074571
PCT Publication Date:June 19, 2014PCT Publication Number: WO2014/093579

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.